8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Feb 10, 2026·SEC
Sutro Biopharma, Inc.(STRO)Earnings, Financials & Key Ratios
STRO•NASDAQ
$30.24
Price updated Jul 7, 2026
AboutSutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Show more
- Revenue$102M+65.2%
- EBITDA-$98M+57.8%
- Net Income-$191M+16.0%
- EPS (Diluted)-22.49+24.0%
- Gross Margin92.85%+5.1%
- EBITDA Margin-95.26%+74.4%
- Operating Margin-102.41%+73.4%
- Net Margin-186.45%+49.1%
STRO Price & Volume
Sutro Biopharma, Inc. (STRO) stock price & volume — 10-year historical chart
Loading chart...
STRO Growth Metrics
Sutro Biopharma, Inc. (STRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.12%
3 Years14.78%
TTM49.94%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM37.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM44.48%
Return on Capital
10 Years-46.35%
5 Years-45.91%
3 Years-53.2%
Last Year-59.29%
STRO Recent Earnings
Sutro Biopharma, Inc. (STRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$2.94-26.7%
$2.32
Rev
$15M+63.3%
$9M
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$5.29-13.5%
$4.66
Rev
$12M+25.8%
$9M
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$5.29+35.2%
$8.16
Rev
$12M+25.8%
$9M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$6.70-59.5%
$4.20
Rev
$10M-4.4%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $2.94vs $2.32-26.7% | $15Mvs $9M+63.3% |
| Q2 2026 | Mar 26, 2026 | $5.29vs $4.66-13.5% | $12Mvs $9M+25.8% |
| Q2 2026 | Mar 23, 2026 | $5.29vs $8.16+35.2% | $12Mvs $9M+25.8% |
| Q4 2025 | Nov 6, 2025 | $6.70vs $4.20-59.5% | $10Mvs $10M-4.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Sutro Biopharma, Inc. (STRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $30.24 | $292.64M | -1.34 | 65.18% | -186.45% | — | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $4.05 | $7.78M | -0.23 | 0.07% | -455.15% | -100.9% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — | |
| $4.75 | $301.92M | -4.03 | 0.78% | -44.79% | -147.8% | — |
Compare STRO vs Peers
Sutro Biopharma, Inc. (STRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STRO SEC Filings & Documents
Sutro Biopharma, Inc. (STRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when STRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STRO Frequently Asked Questions
Sutro Biopharma, Inc. (STRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Sutro Biopharma, Inc.'s revenue?
Sutro Biopharma, Inc. (STRO) reported $99.6M in revenue for fiscal year 2025. This represents a 67% increase from $59.7M in 2016.
How fast is Sutro Biopharma, Inc. growing?
Sutro Biopharma, Inc. (STRO) grew revenue by 65.2% over the past year. This is strong growth.
Is STRO profitable?
Sutro Biopharma, Inc. (STRO) reported a net loss of $153.6M for fiscal year 2025.
Dividend & Returns
What is Sutro Biopharma, Inc.'s free cash flow?
Sutro Biopharma, Inc. (STRO) had negative free cash flow of $152.1M in fiscal year 2025, likely due to heavy capital investments.